Biotech Values

[ghmm]

JB,

My opinion is for an open label study the results are unimpressive. The results aren't statistically significant and do not seem to show great promise. Yeah it will probably go into a larger Phase 2 placebo controlled trial.

I had been a bit leary when I did a little research and saw all those options in the .70's range (I guess they are in the 2.30's now with the reverse split). It doesn't seem they can make any money on Coprexa for Wilson's and so were counting on selling it off-label for IPF. While some can say InterMune did that with Actimmune, its not a good business model to do and I'd imagine they'll run into trouble (can't imagine a partner which they need, have to be very careful in promotion, etc.)

But after seeing the CEO's bio and companies he has been involved with directly and indirectly and other posters on this board being very critical of them (CTIC, DOR) not to mention the photo
http://www.investorshub.com/boards/read_msg.asp?message_id=19895832

I'd be very cautious investing here counting on Coprexa for IPF (perhaps something else in their pipeline has potential I don't follow them that well)!

Disclosure: I am long InterMune